SHTDF (SHTDF) Stock Price & Analysis
SHTDF (SHTDF) rose 0.00% to USD 2.13 as of July 25, 2026 at 15:42 UTC, according to Nexqual real-time market data.
SHTDF last closed at USD 2.13; the session ranged USD 2.3–2.3 on volume of 1,000 shares. Market capitalization is $6.65B, with a 52-week range of USD 2.13–2.7 (PNK). Source: Nexqual, July 25, 2026 at 15:42 UTC.
Key Statistics (as of July 25, 2026 at 15:42 UTC)
| Price | USD 2.13 |
|---|---|
| Change | ▲ 0.00% (up) |
| Previous Close | USD 2.13 |
| Open | USD 2.3 |
| Day Range | USD 2.3 – 2.3 |
| 52-Week Range | USD 2.13 – 2.7 |
| Volume | 1,000 shares |
| Market Cap | $6.65B |
| Exchange | PNK |
Technical Analysis (SHTDF)
Nexqual's technical model rates SHTDF "SELL" based on 2 bullish and 5 bearish signals across 125 daily candles, as of July 25, 2026 at 15:42 UTC.
| Overall Signal | SELL |
|---|---|
| RSI (14) | 0 (oversold) |
| vs SMA50 | Below (USD 2.23) |
| MACD | -0.03 (negative) |
Analyst Ratings (SHTDF)
Wall Street analysts rate SHTDF "None", per Nexqual as of July 25, 2026 at 15:42 UTC.
| Consensus Rating | None |
|---|
Earnings (SHTDF)
| Next Earnings Date | 2026-08-24 |
|---|
Source: Nexqual, July 25, 2026 at 15:42 UTC.
Financials & Fundamentals (SHTDF)
| Total Revenue | $574.27B |
|---|---|
| Revenue Growth (YoY) | -0.60% |
| Gross Margin | +7.17% |
| Operating Margin | +2.18% |
| Profit Margin | +1.24% |
| ROE | +8.10% |
| Debt / Equity | 55.5 |
| Current Ratio | 1.4 |
| Total Cash | $36.37B |
| Total Debt | $75.76B |
| Free Cash Flow | $-2.77B |
Source: Nexqual, July 25, 2026 at 15:42 UTC.
Financial Health Score (SHTDF)
Nexqual rates SHTDF's overall financial health "Weak" across five dimensions, as of July 25, 2026 at 15:42 UTC.
| Growth | Weak — Revenue -2% YoY (annual), declining |
|---|---|
| Profitability | Weak — Gross margin 7%, operating 2% |
| Balance Sheet | Solid — $36.4B cash vs $75.8B debt |
| Cash Flow | Weak — FCF negative: -$2.77B, burning cash |
| Efficiency | Mixed — ROE 8%, ROA 2.6% |
Ownership (SHTDF)
| Insider Ownership | +0.00% |
|---|---|
| Institutional Ownership | +76.19% |
| Shares Outstanding | 1.34B |
| Float | 1.27B |
Source: Nexqual, July 25, 2026 at 15:42 UTC.
Leadership (SHTDF)
SHTDF is led by Wanyong Lian (age 54), President & Executive Director, per Nexqual as of July 25, 2026 at 15:42 UTC.
| President & Executive Director | Wanyong Lian (age 54) |
|---|---|
| Executive Director | Binghua Yang (age 45) |
| Chief Financial Officer | Xiaojuan Li (age 49) |
Major Backers & Investors (SHTDF)
Notable institutional backers of SHTDF include Fidelity, LAZARD FUNDS INC-Lazard Emerging Markets Equity Portfolio, Charles Schwab, according to Nexqual as of July 25, 2026 at 15:42 UTC.
Active Investors
| Investor | Stake |
|---|---|
| Fidelity | 3.87% |
| LAZARD FUNDS INC-Lazard Emerging Markets Equity Portfolio | 3.37% |
| Charles Schwab | 0.76% |
| DFA INVESTMENT DIMENSIONS GROUP INC-Emerging Markets Core Eqy. 2 PORT. | 0.69% |
| American Century ETF Trust-Avantis Emerging Markets Equity ETF | 0.61% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| Vanguard Group | 2.87% |
| BlackRock | 1.02% |
Source: Nexqual, July 25, 2026 at 15:42 UTC.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| SHTDY | Sinopharm Group Co. Ltd. | USD 10.73 | ▼ 0.89% |
| SHPMY | Shanghai Pharmaceuticals Holdin | USD 7.34 | ▲ 0% |
| SFOSF | SHANGHAI FOSUN PHARMACEUTICAL G | USD 2.2 | ▲ 0% |
| CASBF | CANSINO BIOLOGICS INC | USD 3.15 | ▲ 0% |
| SBMFF | SINO BIOPHARMACEUTICAL | USD 0.64 | ▲ 0% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: July 25, 2026 at 15:42 UTC. This page is informational and not investment advice.